Investing.comCodex · 实盘不做把握 4/10
北京时间·🕒 发布 08-03 20:24:29时区推断·⟳ 抓取 08-03 20:25:53·⚡ 决策 08-04 10:18:44 +13h52m·84.3 天前
Royalty Pharma任命Greg Raskin负责学术合作
Royalty Pharma（RPRX.US）任命Greg Raskin为学术计划负责人，属于常规人事与BD渠道建设。
📄 原文Investing.com↗ 原文
Royalty Pharma appoints Greg Raskin to lead academic outreach
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks NEW YORK - Royalty Pharma plc (NASDAQ:RPRX) ann…
不做 Royalty Pharma（RPRX.US）
常规人事任命且临近财报，未披露交易金额、资产获取或财务指引，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 medium ↗
消息传播链
- 媒体报道Royalty Pharma任命Greg Raskin负责Academic Initiatives，未披露新增资产或交易金额。市场反应:RPRX.US当日收跌约2.16%，价格变化与人事任命无清晰因果。
关键理由
- Royalty Pharma（RPRX.US）任命Greg Raskin为学术计划负责人，属于常规人事与BD渠道建设。
- 未披露新增royalty资产、交易金额、产品销售或财务指引。
- 公司将在1天后披露Q2 2026财报，短期股价更可能由财报驱动。
主要风险
- 任命可能长期改善项目来源，但当前没有可回测的1-10日收入或利润传导。
反向证据
- 做多前查反向 · 来源 stock_quote · 日期 2026-08-04 · 影响 weakens
RPRX.US当日下跌约2.16%，但人事任命本身无可量化利好。
检索:RPRX.US stock_quote compact
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 1,924 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
NEW YORK - Royalty Pharma plc (NASDAQ:RPRX) announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective this month, according to a press release statement.
Raskin will lead the company’s outreach efforts with academic and non-profit institutions and oversee the Royalty Pharma Translational Prize. He joins from Memorial Sloan Kettering Cancer Center, where he served as Senior Vice President, Technology Development for over a decade.
At Memorial Sloan Kettering, Raskin led biotechnology startup efforts, technology transfer, monetization and business development. His earlier career included roles as Vice President at AllianceBernstein, where he led healthcare and life sciences investing for the firm’s venture capital fund, and as a biotech analyst at Baker Brothers Investments. He also worked as a management consultant at McKinsey & Company, focusing on pharmaceutical and biotech companies.
"Greg’s experience in licensing and drug development, combined with his investing background, makes him uniquely suited to deepen our engagement with the scientific community," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board.
Raskin received his M.D. from Yale School of Medicine and a B.A. in molecular biophysics and biochemistry from Yale College. He currently serves as a Lecturer in the Department of Economics at Stanford University and Yale University, teaching courses on the economics and science of drug development.
Royalty Pharma, founded in 1996, purchases biopharmaceutical royalties and funds innovation across the industry. The company’s portfolio includes royalties on more than 35 commercial products and 19 development-stage product candidates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Royalty Pharma plc (NASDAQ:RPRX) announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective this month, according to a press release statement.
Raskin will lead the company’s outreach efforts with academic and non-profit institutions and oversee the Royalty Pharma Translational Prize. He joins from Memorial Sloan Kettering Cancer Center, where he served as Senior Vice President, Technology Development for over a decade.
At Memorial Sloan Kettering, Raskin led biotechnology startup efforts, technology transfer, monetization and business development. His earlier career included roles as Vice President at AllianceBernstein, where he led healthcare and life sciences investing for the firm’s venture capital fund, and as a biotech analyst at Baker Brothers Investments. He also worked as a management consultant at McKinsey & Company, focusing on pharmaceutical and biotech companies.
"Greg’s experience in licensing and drug development, combined with his investing background, makes him uniquely suited to deepen our engagement with the scientific community," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board.
Raskin received his M.D. from Yale School of Medicine and a B.A. in molecular biophysics and biochemistry from Yale College. He currently serves as a Lecturer in the Department of Economics at Stanford University and Yale University, teaching courses on the economics and science of drug development.
Royalty Pharma, founded in 1996, purchases biopharmaceutical royalties and funds innovation across the industry. The company’s portfolio includes royalties on more than 35 commercial products and 19 development-stage product candidates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。